Acorda Therapeutics Inc (ACOR)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

420 SAW MILL RIVER ROAD ARDSLEY, NY 10502

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations.

Data based on most recent fiscal year report
Market Cap97.501 Million Shares Outstanding48.03 Million Avg Volume1.956 Million
1-Yr BETA vs S&P TR1.754 Current Ratio3.77 Quick Ratio3.56
View SEC Filings from ACOR instead.

View recent insider trading info

Funds Holding ACOR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACOR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9.6 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BATYCKY RICHARD P.

  • Director
0 2020-01-09 0

CARRAZANA ENRIQUE J.

  • Director
0 2020-01-08 0

GREENE BARRY E PRESIDENT

  • Officer
0 2019-12-23 1

LAWRENCE DAVID CHIEF, BUS. OPS & PAO

  • Officer
12,961 2019-12-02 4

COHEN RON PRESIDENT AND CEO

  • Officer
  • Director
632,437 2019-12-02 4

WASMAN JANE PRESIDENT, INTL AND GC

  • Officer
117,420 2019-12-02 4

SABELLA LAUREN M CHIEF COMMERCIAL OFFICER

  • Officer
12,624 2019-12-02 4

PHILLIPS BARCLAY A

  • Director
0 2019-11-18 0

BLANK BURKHARD CMO AND HEAD OF R&D

  • Officer
0 2019-11-07 2

HINDMAN ANDREW A. SVP, CHIEF FINANCIAL OFFICER

  • Officer
50,000 2019-07-01 2

ROGERS MICHAEL W

0 2019-06-25 0

PANEM SANDRA PHD

  • Director
0 2019-06-19 1

JENSEN PEDER

  • Director
0 2019-06-19 2

KELLEY JOHN P

  • Director
0 2019-06-19 1

RAUSCHER STEVEN M

  • Director
0 2019-06-19 1

RANDALL LORIN

  • Director
0 2019-06-19 1

STRADER CATHERINE D.

  • Director
0 2019-06-19 1

SCOPIA CAPITAL MANAGEMENT LP

SCOPIA MANAGEMENT, INC.

SIROVICH MATTHEW

MINDICH JEREMY

  • 10% Owner
3,927,457 2019-05-28 0

SMITH IAN F EVP, COO

  • Officer
52,005 2018-06-29 0

WESSEL THOMAS CHIEF MEDICAL OFFICER

  • Officer
0 2018-01-17 0

BLIGHT ANDREW CHIEF SCIENTIFIC OFFICER

  • Officer
78,594 2017-03-01 0

YOUNG WISE

  • Director
17,307 2010-06-09 0

RIDGEBACK CAPITAL INVESTMENTS LTD.

RIDGEBACK CAPITAL MANAGEMENT LLC

HOLMAN WAYNE GEORGE

  • 10% Owner
No longer subject to file 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

WASMAN JANE - Officer PRESIDENT, INTL AND GC

2019-12-02 S 2,227 $1.60 d 117,420 117,420.00 direct

LAWRENCE DAVID - Officer CHIEF, BUS. OPS & PAO

2019-12-02 S 1,176 $1.60 d 12,961 12,961.00 direct

SABELLA LAUREN M - Officer CHIEF COMMERCIAL OFFICER

2019-12-02 S 1,513 $1.60 d 12,624 12,624.00 direct

COHEN RON - Director - Officer PRESIDENT AND CEO

2019-12-02 S 4,699 $1.60 d 607,287 632,437.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments